Effect of Bortezomib Regimens and Daratumumab Monotherapy on Cellular Immunity in Multiple Myeloma Patients

CONCLUSION: Bortezomib had a negative influence on subsets of T cells, while Daratumumab positively affected T cells subsets. In both treatments, NK cells decreased significantly. These results suggested that DARA is more specific to target myeloma cells than Bortezomib. Also, DARA expanded T cells especially CD3+ T cells and CD4+ T cells.PMID:34190693 | DOI:10.22034/iji.2021.87547.1812
Source: Iranian Journal of Immunology - Category: Allergy & Immunology Authors: Source Type: research